The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty-five (35) at the time of initiation of GLP-1 therapy, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to thirty (30) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Heart failure with preserved ejection fraction, uncontrolled hypertension (defined as systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg, despite concurrent treatment with two antihypertensive medications , or chronic kidney disease stage 3a or above, or The beneficiary is at least eighteen (18) years of age and has a BMI greater than or equal to twenty-seven (27) at the time of initiating GLP-1 therapy with a diagnosis of one or more of the following: Pre-diabetes (as defined by American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease
Women who lost more than 15% body weight showed higher rates of temporary amenorrhea, which normalized as weight stabilized
According to the manufacturers of Ozempic and Wegovy, the main common side effects may include: Nausea, vomiting, and diarrhea that could lead to an acute kidney injury Dizziness Rapid heart rate Headaches Hypoglycemia Allergic reactions to the medication Abdominal pain Shortness of breath Severe hypoglycemia Blurred vision Severe rash Slurred speech Hoarse voice Other minor side effects to watch out for include a rise in resting heart rate, a decrease in heart rate variability, and mood changes (like anxiety and depression)
OR 2 = 0.21 [95% CI 0.050.92], P 2 = 3.89 10 2 )
Using our online scheduler, choose your vitamin drip, add any boosters, then pick a date and time that works for you
Sandeep Taks Post TRIUMPH-1 trial results: Retatrutide, the triple agonist
